TY - JOUR
T1 - A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus
AU - Steel, John
AU - Burmakina, Svetlana V.
AU - Thomas, Colleen
AU - Spackman, Erica
AU - García-Sastre, Adolfo
AU - Swayne, David E.
AU - Palese, Peter
N1 - Funding Information:
We thank Joan Beck for excellent technical assistance. This work was supported by grants (to A.G.-S. and P.P.) from the National Institutes of Health (NIH), and the U.S. Department of Agriculture, Agricultural Research Service (D.S.). P.P is a senior fellow of the Ellison Medical Foundation. Partial support of this work was provided by NIH grants UO1AI070469 (Live Attenuated Vaccines for Epidemic and Pandemic Flu), HHSN2662000700010C (Center for Research on Influenza Pathogenesis), U54 AI057158-04 (Northeast Biodefense Center) and 1 UC19 AI062623-023 (Center For Investigating Viral Immunity and Antagonism).
PY - 2008/1/24
Y1 - 2008/1/24
N2 - The protection of poultry from H5N1 highly pathogenic avian influenza A (HPAI) and Newcastle disease virus (NDV) can be achieved through vaccination, as part of a broader disease control strategy. We have previously generated a recombinant influenza virus expressing, (i) an H5 hemagglutinin protein, modified by the removal of the polybasic cleavage peptide and (ii) the ectodomain of the NDV hemagglutinin-neuraminidase (HN) protein in the place of the ectodomain of influenza neuraminidase (Park MS, et al. Proc Natl Acad Sci USA 2006;103(21):8203-8). Here we show this virus is attenuated in primary normal human bronchial epithelial (NHBE) cell culture, and demonstrate protection of C57BL/6 mice from lethal challenge with an H5 HA-containing influenza virus through immunisation with the recombinant virus. In addition, in-ovo vaccination of 18-day-old embryonated chicken eggs provided 90% and 80% protection against highly stringent lethal challenge by NDV and H5N1 virus, respectively. We propose that this virus has potential as a safe in-ovo live, attenuated, bivalent avian influenza and Newcastle disease virus vaccine.
AB - The protection of poultry from H5N1 highly pathogenic avian influenza A (HPAI) and Newcastle disease virus (NDV) can be achieved through vaccination, as part of a broader disease control strategy. We have previously generated a recombinant influenza virus expressing, (i) an H5 hemagglutinin protein, modified by the removal of the polybasic cleavage peptide and (ii) the ectodomain of the NDV hemagglutinin-neuraminidase (HN) protein in the place of the ectodomain of influenza neuraminidase (Park MS, et al. Proc Natl Acad Sci USA 2006;103(21):8203-8). Here we show this virus is attenuated in primary normal human bronchial epithelial (NHBE) cell culture, and demonstrate protection of C57BL/6 mice from lethal challenge with an H5 HA-containing influenza virus through immunisation with the recombinant virus. In addition, in-ovo vaccination of 18-day-old embryonated chicken eggs provided 90% and 80% protection against highly stringent lethal challenge by NDV and H5N1 virus, respectively. We propose that this virus has potential as a safe in-ovo live, attenuated, bivalent avian influenza and Newcastle disease virus vaccine.
KW - Avian influenza
KW - In-ovo
KW - NDV
UR - http://www.scopus.com/inward/record.url?scp=37849050476&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.11.032
DO - 10.1016/j.vaccine.2007.11.032
M3 - Article
C2 - 18093698
AN - SCOPUS:37849050476
SN - 0264-410X
VL - 26
SP - 522
EP - 531
JO - Vaccine
JF - Vaccine
IS - 4
ER -